News articles about Pulmatrix (NASDAQ:PULM) have been trending somewhat positive this week, according to Alpha One. The research group, a service of Accern, identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pulmatrix earned a media sentiment score of 0.14 on Alpha One’s scale. Alpha One also assigned news coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected AlphaOne Sentiment Analysis’s rankings:
- Chronic Obstructive Pulmonary Disease – Pipeline Review, H1 2017 – New Market Study Published (sbwire.com)
- Technical Reports on Biotech Equities — Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ (ih.advfn.com)
- PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc. (finance.yahoo.com)
Shares of Pulmatrix (NASDAQ:PULM) traded down 0.83% during mid-day trading on Friday, hitting $2.40. The stock had a trading volume of 209,219 shares. Pulmatrix has a one year low of $0.50 and a one year high of $6.98. The firm has a 50 day moving average of $2.64 and a 200 day moving average of $2.50. The stock’s market cap is $45.89 million.
Pulmatrix (NASDAQ:PULM) last announced its earnings results on Friday, May 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 164.91% and a negative net margin of 3,328.91%. On average, analysts forecast that Pulmatrix will post ($4.13) earnings per share for the current year.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.